Literature DB >> 13704181

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent.

E A GEHAN.   

Abstract

Entities:  

Keywords:  PHARMACOLOGY

Mesh：

Substances：

Year:  1961        PMID： 13704181     DOI： 10.1016/0021-9681(61)90060-1

Source DB:  PubMed          Journal:  J Chronic Dis        ISSN： 0021-9681


× No keyword cloud information.
  131 in total

Review 1.  Stopping rules for phase II studies.

Authors:  N Stallard; J Whitehead; S Todd; A Whitehead
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

2.  A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer.

Authors:  G Schwartsmann; H Schunemann; C N Gorini; A F Filho; C Garbino; G Sabini; I Muse; L DiLeone; D R Mans
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

3.  The practical application of adaptive study design in early phase clinical trials: a retrospective analysis of time savings.

Authors:  U Lorch; K Berelowitz; C Ozen; A Naseem; E Akuffo; J Taubel
Journal:  Eur J Clin Pharmacol       Date:  2011-11-25       Impact factor: 2.953

4.  An adaptive design for phase II non-oncology dose selection clinical trials.

Authors:  Zheng Su
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

5.  Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity.

Authors:  Xiudong Lei; Ying Yuan; Guosheng Yin
Journal:  Lifetime Data Anal       Date:  2010-04-03       Impact factor: 1.588

6.  Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma.

Authors:  G H Mickisch; M A Noordzij; A vd Gaast; P Gebreamlack; K U Köhrmann; E Mogler-Drautz; H Kupper; F H Schröder
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

7.  Activity of the Janus kinase inhibitor ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.

Authors:  David E Spaner; Guizhei Wang; Lindsay McCaw; Yanmei Li; Patricia Disperati; Mary-Ann Cussen; Yonghong Shi
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

8.  High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.

Authors:  Lauren E Abrey; Barrett H Childs; Nina Paleologos; Lynne Kaminer; Steven Rosenfeld; Donna Salzman; Jonathan L Finlay; Sharon Gardner; Kendra Peterson; Wendy Hu; Lode Swinnen; Robert Bayer; Peter Forsyth; Douglas Stewart; Anne M Smith; David R Macdonald; Susan Weaver; David A Ramsey; Stephen D Nimer; Lisa M DeAngelis; J Gregory Cairncross
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

9.  A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation.

Authors:  Chunyan Cai; Suyu Liu; Ying Yuan
Journal:  Stat Med       Date:  2014-05-12       Impact factor: 2.373

10.  Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.